Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 17/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | LATS1 | O95835 | 1/20 | 0.46 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29619213 | 0.85 | LATS1 (0.59) | GBA1ADORA3ADORA2AADORA1LATS1 | |
| SCHEMBL29619237 | 0.84 | IRAK1 (0.42) | GBA1ADORA3ADORA2AADORA1LATS1 | |
| SCHEMBL29619202 | 0.81 | GBA1 (0.56) | GBA1ADORA3ADORA2AADORA1LATS1 | |
| SCHEMBL30085660 | 0.80 | GBA1 (0.56) | GBA1ADORA3ADORA2AADORA1LATS1 | |
| SCHEMBL22428611 | 0.79 | ADORA3 (0.47) | ADORA3ADORA2AADORA1LATS1LATS2 | |
| SCHEMBL29619244 | 0.79 | ADORA3 (0.47) | ADORA3ADORA2AADORA1LATS1LATS2 | |
| SCHEMBL24421546 | 0.76 | GBA1 (0.52) | GBA1ADORA3ADORA2AADORA1LMNA | |
| SCHEMBL29363033 | 0.76 | GBA1 (0.52) | GBA1ADORA3ADORA2AADORA1LMNA | |
| SCHEMBL18354085 | 0.76 | GBA1 (1.00) | GBA1 | |
| SCHEMBL18353876 | 0.75 | GBA1 (1.00) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3938340-B1 | HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS | COLLABORATIVE MEDICINAL DEV LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20220144826-A1 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144826-A1 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | AIFM2, FECH, SLC40A1 | GBA1 1015/4885ADORA3 1623/4885ADORA2A 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.